SCHEMBL5017672

SCHEMBL5017672

CS(=O)(=O)c1nc(N)cc(-c2ccncc2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BPTF Q12830 2/20 0.47
LMNA P02545 5/20 0.46
KMT2A Q03164 5/20 0.46
NPSR1 Q6W5P4 5/20 0.46
SDHB P21912 4/20 0.46
TP53 P04637 4/20 0.46
HPGD P15428 4/20 0.46
RAB9A P51151 3/20 0.46
HTT P42858 3/20 0.46
HSD17B10 Q99714 3/20 0.46
STAT3 P40763 2/20 0.46
STAT1 P42224 2/20 0.46
TLR9 Q9NR96 2/20 0.46
S1PR4 O95977 2/20 0.46
S1PR1 P21453 2/20 0.46
MAPK1 P28482 2/20 0.46
MEN1 O00255 1/20 0.46
POLB P06746 1/20 0.46
KDM4E B2RXH2 4/20 0.44
ALDH1A1 P00352 4/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5017675 0.83 LMNA (0.50) BPTFLMNAKMT2ANPSR1SDHB
SCHEMBL5592833 0.82 BPTF (0.63) BPTFLMNAKMT2ANPSR1SDHB
SCHEMBL3825032 0.78 LMNA (0.62) BPTFLMNAKMT2ANPSR1SDHB
SCHEMBL21020091 0.75 KDM4E (0.67) LMNAKMT2ANPSR1SDHBTP53
SCHEMBL5022939 0.75 CCR1 (0.44) BPTFLMNAKMT2ANPSR1SDHB
SCHEMBL28146826 0.75 NPC1 (0.45) BPTFLMNAKMT2ANPSR1SDHB
SCHEMBL18893679 0.74 SMN1; SMN2 (0.45) BPTFLMNAKMT2ANPSR1SDHB
SCHEMBL5022567 0.73 ADORA2A (0.68) LMNAKMT2AHPGDMEN1KDM4E
SCHEMBL30505019 0.73 KDM5B (0.41) BPTFMAPK1
SCHEMBL5022932 0.71 MAPT (0.65) KMT2ANPSR1TP53HPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
CN-1953975-A 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists ALMIRALL PRODESFARMA AG (CH) 2007-04-25 CN disclosed
EP-1697351-A1 2,6-BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS Almirall Prodesfarma AG (CH) 2006-09-06 EP disclosed
WO-2005058883-A1 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL PRODESFARMA AG (CH) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists ADORA2A, ADORA3, ADORA1 BPTF 3154/4885LMNA 4748/4885KMT2A 1799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.